MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

FACIAL EMOTION EXPRESSIVITY IN PARKINSON’S AND ALZHEIMER’S DISEASES

A. Cannavacciuolo, A. Guerra, D. Colella, M. Salzillo, A. de Biase, G. Paparella, M. Canevelli, G. Bruno, A. Berardelli, M. Bologna (Pozzilli, Italy)

Meeting: 2022 International Congress

Abstract Number: 1516

Keywords: Behavioral abnormalities, Dementia, Parkinson’s

Category: Parkinson's Disease: Pathophysiology

Objective: We here aimed to comprehensively investigate facial emotion expressivity in Parkinson’s disease (PD) and Alzheimer’s disease (AD) patients compared to healthy controls (HCs).

Background: Among motor symptoms, one of the most prominent features in PD is reduced facial expressivity, e.g., hypomimia. Although parkinsonian signs and symptoms are relatively common in AD, no study has specifically assessed the possible occurrence of reduced facial expressivity in these patients.

Method: Twenty-four PD patients (17 M, mean age ± standard deviation:73.83±4.2 years), 24 AD patients(9 M, 77.79±7.8 years), and 24 HCs(13 M, 72.96±7.1 years) were video-recorded while posing facial expressions of six primary emotions (anger, disgust, fear, happiness, sadness, surprise) and neutral expressions. Ten neurologists were screened for the ability to recognize facial expressions during an Emotion Recognition Task (ERT) and then asked to identify the emotion of the participants’ pictures in a seven-forced-choice response format (Emotion Expressivity Task-EET). Accuracy of responses, reaction times, and confidence levels in the response were considered in the analysis(Fig.1).

Results: The overall ERT score was higher than 80% (range:72-93%). In the EET, raters identified a lower number of correct responses in PD and in AD than in HCs (37%,36% and 52% respectively, p<0.01) with no differences between PD and AD (p=0.61)(Fig.2). We also found longer reaction times for the evaluation of patients compared to HCs’ pictures(p<0.05).Finally, the pattern of reduced facial emotion expressivity between PD and AD was similar(Fig.3).

Conclusion: Along with the confirmation of reduced facial expressivity in PD, the study provides evidence of a similar motor abnormality in AD. The facial expressivity deficit in PD and AD may result from common pathophysiology or a manifestation of distinct mechanisms. Further studies should better delineate the clinical relevance of reduced facial expressivity in AD.

Figure 2

Figure 1

Figure 3

References: Ricciardi L, Visco-Comandini F, Erro R, Morgante F, Bologna M, Fasano A, Ricciardi D, Edwards MJ, Kilner J. Facial Emotion Recognition and Expression in Parkinson’s Disease: An Emotional Mirror Mechanism? PLoS One. 2017 Jan 9;12(1):e0169110. doi: 10.1371/journal.pone.0169110. PMID: 28068393; PMCID: PMC5221788.
Bologna M, Merola A, Ricciardi L. Behavioral and Emotional Dysfunction in Parkinson’s Disease. Parkinsons Dis. 2019 Jun 18;2019:1749525. doi: 10.1155/2019/1749525. PMID: 31316745; PMCID: PMC6604351.

To cite this abstract in AMA style:

A. Cannavacciuolo, A. Guerra, D. Colella, M. Salzillo, A. de Biase, G. Paparella, M. Canevelli, G. Bruno, A. Berardelli, M. Bologna. FACIAL EMOTION EXPRESSIVITY IN PARKINSON’S AND ALZHEIMER’S DISEASES [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/facial-emotion-expressivity-in-parkinsons-and-alzheimers-diseases/. Accessed September 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/facial-emotion-expressivity-in-parkinsons-and-alzheimers-diseases/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Carpal Tunnel Syndrome in Patients with Tremor
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • #22892 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley